Robuta

https://www.capricor.com/ Capricor Therapeutics, Inc. (CAPR) therapeutics inccapr https://www.aldeyra.com/ Medicines to Treat Immune-Mediated Diseases | Aldeyra Therapeutics, Inc. Oct 28, 2025 - Learn more about Aldeyra Therapeutics, devoted to inventing, developing, and commercializing next-generation medicines that treat immune-mediated disease. immune mediated diseasestreat https://www.vistex.com/blog/life-sciences/digital-health-and-therapeutics-dtx/ Doctor Byte: What’s Next In Digital Health And Digital Therapeutics (DTx) - Vistex, Inc Jun 6, 2024 - Digital health and digital therapeutics (DTx) will transform healthcare as we know it. Opportunities already exist and will play a part in life sciences and... digital healthdoctorbytenext https://www.collaborativedrug.com/cdd-blog/cdd-spotlight-interview-with-dale-cameron-vida-therapeutics-inc CDD Spotlight Interview with Dale Cameron, viDA Therapeutics Inc. cdd spotlight interviewdale https://cogrx.com/ Cognition Therapeutics, Inc. therapeutics inccognition https://www.protagonist-inc.com/ Protagonist Therapeutics Inc. Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing... therapeutics incprotagonist https://www.prweb.com/releases/incregen-therapeutics-advances-first-in-class-gip-ligand-antagonist-inc-118-into-ind-enabling-development-to-address-long-term-obesity-management-302655010.html Incregen Therapeutics Advances First-in-Class GIP Ligand Antagonist INC-118 into IND-Enabling... /PRNewswire-PRWeb/ -- Incregen Therapeutics Advances First-in-Class GIP Ligand Antagonist INC-118 into IND-Enabling Development to Address Long-Term Obesity... therapeuticsadvancesfirstgip https://www.leaptx.com/ Leap Therapeutics, Inc. Jan 29, 2025 - Leap Therapeutics (Nasdaq: LPTX) is developing targeted therapy for cancer patients with DKK1expressing tumors. Leap’s DKN-01 targets the DKK1 protein. therapeutics incleap https://www.sangamo.com/ Sangamo Therapeutics, Inc. | Pioneering Genetic Cures Feb 28, 2026 - Sangamo uses a multi-platform approach to gene-based therapeutics with industry leading technologies in gene therapy, gene editing, cell therapy and gene... therapeutics incsangamocures https://www.vistex.com/resources/digital-therapeutics/ Dr. Byte: Insights into What’s Next in Digital Therapeutics - Vistex, Inc drbyteinsightsnextdigital